Modality
Degrader
MOA
AHRant
Target
BCL-2
Pathway
Apoptosis
Angelman
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
Jan 2018
→ May 2031
Phase 1Current
NCT05667060
2,729 pts·Angelman
2018-01→2031-05·Completed
2,729 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-05-235.1y awayInterim· Angelman
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1
Complet…
Catalysts
Interim
2031-05-23 · 5.1y away
Angelman
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05667060 | Phase 1 | Angelman | Completed | 2729 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-8550 | Roche | Approved | BCL-2 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Bemaderotide | Revolution Medicines | Phase 3 | BCL-2 |